Montchanin Asset Management, LLC Durect Corp Transaction History

Montchanin Asset Management, LLC

  • $109 Million
  • Q3 2024

A detailed history of Montchanin Asset Management, LLC transactions in Durect Corp stock. As of the latest transaction made, Montchanin Asset Management, LLC holds 304,032 shares of DRRX stock, worth $297,951. This represents 0.38% of its overall portfolio holdings.

Number of Shares
304,032
Previous 301,852 0.72%
Holding current value
$297,951
Previous $389,000 4.63%
% of portfolio
0.38%
Previous 0.37%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$1.12 - $1.67 $2,441 - $3,640
2,180 Added 0.72%
304,032 $407,000
Q2 2024

Jul 19, 2024
BUY
$0.77 - $1.78 $24,448 - $56,516
31,751 Added 11.76%
301,852 $389,000
Q1 2024

May 16, 2024
BUY
$0.52 - $1.37 $80,422 - $211,882
154,659 Added 133.97%
270,101 $327,000
Q2 2023

Aug 16, 2023
BUY
$4.05 - $7.0 $27,216 - $47,040
6,720 Added 6.18%
115,442 $571,000
Q1 2023

May 10, 2023
BUY
$3.6 - $8.72 $167,666 - $406,125
46,574 Added 74.94%
108,722 $457,000
Q4 2022

Feb 16, 2023
SELL
$0.39 - $6.5 $180,516 - $3.01 Million
-462,863 Reduced 88.16%
62,148 $215,000
Q3 2022

Nov 16, 2022
BUY
$0.43 - $5.9 $17,365 - $238,277
40,386 Added 8.33%
525,011 $304,000
Q2 2022

Aug 16, 2022
BUY
$0.38 - $0.64 $184,157 - $310,160
484,625 New
484,625 $232,000

Others Institutions Holding DRRX

# of Institutions
3
Shares Held
593K
Call Options Held
0
Put Options Held
0
View Full List

About DURECT CORP

DRRX Quotes by TradingView
  • Ticker DRRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 227,794,000
  • Market Cap $223M
  • Description
  • DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...
More about DRRX
Track This Portfolio

Track Montchanin Asset Management, LLC Portfolio

Follow Montchanin Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Montchanin Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Montchanin Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email